AlphaValue Corporate Services
This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things are getting going...hopefully in FY25
Target
Upside 291%
Price (€) 1.88
Market Cap (€M) 84.6
Perf. 1W: -8.10%
Perf. 1M: -10.3%
Perf. 3M: -7.65%
Perf Ytd: -15.1%
10 day relative perf. to stoxx600: -8.43%
20 day relative perf. to stoxx600: -18.9%
EPS change26/09/2022 13:38

Minor changes after H1 22

Change in EPS2022 : € -0.32 vs -0.23ns
2023 : € -0.35 vs -0.25ns

We have only changed our short-term estimates after the release of the H1 22 results. These changes are minor and are limited to FY23-24) even if they look more significant in EPS terms due to the fact that the result is a small loss, implying that any change to our numbers translates into an apparent bigger change in percentage terms. The impact on our valuation of the stock is thus marginal.



.